TW201722989A - 抗il-2抗體及其組合物及用途 - Google Patents

抗il-2抗體及其組合物及用途 Download PDF

Info

Publication number
TW201722989A
TW201722989A TW105134200A TW105134200A TW201722989A TW 201722989 A TW201722989 A TW 201722989A TW 105134200 A TW105134200 A TW 105134200A TW 105134200 A TW105134200 A TW 105134200A TW 201722989 A TW201722989 A TW 201722989A
Authority
TW
Taiwan
Prior art keywords
seq
antibody
nos
hil
binding portion
Prior art date
Application number
TW105134200A
Other languages
English (en)
Chinese (zh)
Inventor
艾薩克 J 朗頓
納塔莎 奎林
保羅 貝賽特
艾雷諾拉 特洛塔
傑弗瑞 A 布魯斯東
羅倫 Ｋ 艾利
肯南 克利斯多弗 葛西亞
Original Assignee
輝瑞大藥廠
美國加利福尼亞大學董事會
李蘭. 史丹佛學院理事會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 輝瑞大藥廠, 美國加利福尼亞大學董事會, 李蘭. 史丹佛學院理事會 filed Critical 輝瑞大藥廠
Publication of TW201722989A publication Critical patent/TW201722989A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
TW105134200A 2015-10-23 2016-10-21 抗il-2抗體及其組合物及用途 TW201722989A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562245600P 2015-10-23 2015-10-23
US201662408360P 2016-10-14 2016-10-14

Publications (1)

Publication Number Publication Date
TW201722989A true TW201722989A (zh) 2017-07-01

Family

ID=57233907

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105134200A TW201722989A (zh) 2015-10-23 2016-10-21 抗il-2抗體及其組合物及用途

Country Status (9)

Country Link
US (4) US10138298B2 (enExample)
EP (1) EP3365369A1 (enExample)
JP (1) JP7030689B2 (enExample)
KR (2) KR102876923B1 (enExample)
CN (2) CN115636880A (enExample)
AU (2) AU2016340989B2 (enExample)
CA (1) CA2946113A1 (enExample)
TW (1) TW201722989A (enExample)
WO (1) WO2017070561A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN110087681A (zh) 2016-09-28 2019-08-02 佐马美国有限公司 结合白细胞介素-2的抗体和其用途
CA3048186A1 (en) * 2016-12-23 2018-06-28 Cephalon, Inc. Anti-il-5 antibodies
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US11117958B2 (en) 2017-05-25 2021-09-14 Institute For Basic Science Anti-human interleukin-2 antibodies and uses thereof
PH12020550661A1 (en) 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
AU2019233576A1 (en) * 2018-03-13 2020-09-17 Cancer Research Technology Limited Anti-CD25 for tumour specific cell depletion
SG11202107272SA (en) * 2019-02-01 2021-07-29 Regeneron Pharma Anti-il2 receptor gamma antigen-binding proteins
CA3134439A1 (en) * 2019-03-29 2020-10-08 Institut Curie Interleukin-2 variants with modified biological activity
WO2020210843A2 (en) 2019-04-12 2020-10-15 The Johns Hopkins University Tolerogenic artificial antigen-presenting cells
US12151000B2 (en) * 2019-04-12 2024-11-26 The Johns Hopkins University Tolerogenic artificial antigen-presenting cells
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
KR20220034133A (ko) * 2019-06-26 2022-03-17 더 존스 홉킨스 유니버시티 조절 t 세포의 표적화된 확장을 위한 방법 및 재료
CN114364694B (zh) * 2019-07-12 2024-05-10 国立大学法人京都大学 靶向usag-1分子的用于牙齿再生治疗的中和抗体
CN115768483A (zh) 2020-01-13 2023-03-07 西纳福克斯股份有限公司 抗体与免疫细胞衔接器的缀合物
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine, Inc. Biased il2 muteins methods and compositions
KR20220143869A (ko) * 2020-02-21 2022-10-25 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-il-2 항체, 이의 항원-결합 단편 및 이의 의학적 용도
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
EP4139354A4 (en) * 2020-04-24 2024-05-29 University of Central Florida Research Foundation, Inc. IL-2 TARGETING CD25 TO INCREASE CD4 T CELL FORMATION AND TREATMENT OF INFECTIONS
CN116783213A (zh) * 2020-08-18 2023-09-19 苏黎世大学 Cd25偏向的抗il‐2抗体
CA3189257A1 (en) 2020-08-18 2022-02-24 Universitat Zurich A cd25-biased anti-il-2 antibody
JP2024506022A (ja) 2021-02-08 2024-02-08 シンアフィックス ビー．ブイ． 多機能性抗体
EP4130038A1 (en) * 2021-08-03 2023-02-08 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Anti-il-2 antibody, complex comprising it, and uses thereof
EP4393949A4 (en) * 2021-08-25 2025-01-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION WITH FUSION PROTEIN
KR20240049342A (ko) * 2021-08-27 2024-04-16 얀센 바이오테크 인코포레이티드 항-psma 항체 및 이의 용도
CA3234995A1 (en) * 2021-10-14 2023-04-20 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
WO2023122653A1 (en) * 2021-12-23 2023-06-29 Arizona Board Of Regents On Behalf Of Arizona State University Compositions and methods for delivery of il-2 and anti-il-2 for treatment of rheumatoid arthritis
CN115850471B (zh) * 2022-10-13 2026-04-07 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
CN120329440A (zh) * 2024-01-18 2025-07-18 烁微生物医药(上海)有限公司 特异性结合hEGFR的单克隆抗体及双特异性抗体
CN118515762B (zh) * 2024-07-23 2024-11-01 北京百普赛斯生物科技股份有限公司 特异性结合il-2的抗体及其应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
EP0737750B1 (en) 1989-03-21 2003-05-14 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
EP0695169B1 (en) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0711829A3 (en) 1993-09-15 1997-07-09 Viagene Inc Recombinant alphavirus vector
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
JP3002702B2 (ja) 1993-11-16 2000-01-24 スカイファーム インコーポレーテッド 活性物質の制御放出を有する小胞
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP2270048B1 (en) 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
KR101374514B1 (ko) * 2003-12-10 2014-03-13 메다렉스, 인코포레이티드 Ｉｐ―１０ 항체 및 그의 용도
AU2005205533B2 (en) * 2004-01-07 2012-03-22 Novartis Vaccines And Diagnostics, Inc. M-CSF-specific monoclonal antibody and uses thereof
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
US7314622B2 (en) 2005-04-15 2008-01-01 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
EP1888644A1 (en) * 2005-06-01 2008-02-20 Micromet AG Anti-il2 antibodies
CN101573139A (zh) 2006-02-16 2009-11-04 纳森特生物制剂公司 在哺乳动物个体中改善免疫功能的方法以及预防或治疗疾病的方法
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
JP5785493B2 (ja) 2008-09-17 2015-09-30 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法
SI3715345T1 (sl) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Priprava zaviralca lfa-1
WO2014028748A1 (en) * 2012-08-15 2014-02-20 Irm Llc Interleukin 2 antibodies and antibody complexes
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Also Published As

Publication number Publication date
EP3365369A1 (en) 2018-08-29
US20230340106A1 (en) 2023-10-26
AU2016340989B2 (en) 2023-09-14
WO2017070561A1 (en) 2017-04-27
KR20180064541A (ko) 2018-06-14
CN109071648A (zh) 2018-12-21
KR20250154564A (ko) 2025-10-28
US10138298B2 (en) 2018-11-27
KR102876923B1 (ko) 2025-10-28
CN109071648B (zh) 2022-07-19
US20170114130A1 (en) 2017-04-27
JP2018537962A (ja) 2018-12-27
CA2946113A1 (en) 2017-04-23
NZ741404A (en) 2024-03-22
US20210061902A1 (en) 2021-03-04
AU2023219940A1 (en) 2023-10-12
US12595301B2 (en) 2026-04-07
US10738113B2 (en) 2020-08-11
JP7030689B2 (ja) 2022-03-07
CN115636880A (zh) 2023-01-24
US11459385B2 (en) 2022-10-04
US20190106488A1 (en) 2019-04-11
AU2016340989A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
US12595301B2 (en) Anti-il-2 antibodies and compositions and uses thereof
US12372536B2 (en) Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
ES2932602T3 (es) Anticuerpos contra la proteína alfa reguladora de señales y métodos de uso
AU2016307845B2 (en) Anti-TIGIT antibodies
WO2015109212A1 (en) Anti-il-2 antibodies and compositions and uses thereof
AU2014348676A1 (en) Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
KR20200083598A (ko) 이뮤노글로불린-유사 전사체 3 (ilt3)에 대해 특이적인 항체 및 그의 용도
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
JP2016520058A (ja) 抗グルカゴン受容体抗体およびその使用方法
WO2025262564A1 (en) Use of anti-cxcr5 antibodies
HK1227416A1 (en) Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
HK1227416B (zh) 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途